Why the study?
The emergence of SARS-CoV and SARS-CoV-2 highlighted the need to develop universal vaccination strategies against the broader Sarbecovirus subgenus.
Does chimeric spike mRNA vaccination protect against Sarbecovirus challenge in vulnerable aged mice?
Population
Vulnerable aged mice
Comparison
Chimeric spike mRNA vaccines vs SARS-CoV-2 mRNA vaccination
Design
Preclinical animal challenge study
Key result
Chimeric spike mRNA vaccines completely protected aged mice against challenge from SARS-CoV, SARS-CoV-2, and bat coronaviruses, whereas monovalent SARS-CoV-2 vaccines resulted in breakthrough infections with heterologous viruses.
Authors
Loading...
Supports chimeric spike vaccine development for broad Sarbecovirus protection; leaves open human translation and clinical efficacy.
Does chimeric spike mRNA vaccination protect against Sarbecovirus challenge in vulnerable aged mice?
Multiplexed-chimeric spike mRNA vaccines can prevent SARS-like zoonotic coronavirus infections with pandemic potential in mice.
Martinez et al. (2021) studied Sarbecovirus infection. Chimeric spike mRNA-LNP vaccines vs. Monovalent SARS-CoV-2 mRNA vaccine or norovirus GII capsid vaccine was evaluated on Protection against weight loss and viral replication following Sarbecovirus challenge. Chimeric spike mRNA vaccines completely protected aged mice against challenge from SARS-CoV, SARS-CoV-2, and bat coronaviruses, whereas monovalent SARS-CoV-2 vaccines resulted in breakthrough infections with heterologous viruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: